Endo sues Zydus in patent battle over methods of purifying generic version of recalled smoking cessation drug Chantix

En­do In­ter­na­tion­al, which lost a patent bat­tle last year over its va­so­pressin in­jec­tion Va­sostrict, is back in court — this time su­ing Zy­dus Phar­ma­ceu­ti­cals for patent in­fringe­ment over its gener­ic ver­sion of Pfiz­er’s smok­ing-ces­sa­tion drug Chan­tix.

En­do’s gener­ic drug mak­ing sub­sidiary Par Phar­ma­ceu­ti­cal filed its com­plaint on Aug. 8 in Delaware Dis­trict Court against Zy­dus, al­leg­ing that Zy­dus’ gener­ic in­fringes on En­do’s re­cent­ly-filed patent for how to pu­ri­fy the drug. En­do has al­so asked for an un­spec­i­fied amount of dam­ages and that Zy­dus’ gener­ic be tak­en off of the mar­ket.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.